NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Search Results for Plenaxis


Results 1 - 9


 Refine Search
Display Mode: Context | Summary
Praecis Pharmaceuticals reports third quarter 2006 net loss of $6.7 million
2006 DEC 11 ... 2006 was due primarily to a decrease in product sales and licensing revenues related to Plenaxis. Also contributing to the increased net loss for the third quarter was incremental ...
Subject: Business & Finance
Price: $3.00
*
Praecis Pharmaceuticals reports second quarter 2006 financial results
2006 SEP 4 ... the company announced that it would cease its active efforts to license or sell its Plenaxis assets. As a result, the company has recorded various non-cash and other charges ...
Subject: Finance
Price: $3.00
*
Biopharma developer reports net loss in third quarter
2005 DEC 5 ... related principally to the voluntary discontinuation of promotional activities for Plenaxis in the United States and a reduction in headcount in May 2005. Expenses incurred during ...
Subject: Finance
Price: $3.00
*
Pharma company receives marketing authorization for Plenaxis in Germany
2005 OCT 24 ... Incorporated (PRCS) announced that it has received marketing authorization for Plenaxis (abarelix 100 mg powder for an injectable suspension) from the German competent ...
Subject: Prostate Cancer
Price: $3.00
*
Pharma company reports financial results
2005 SEP 5 ... while also continuing to seek a commercially acceptable marketing approval for Plenaxis in Germany in collaboration with Schering AG. As part of the strategic ...
Subject: Finance
Price: $3.00
*
Pharma company announces restructuring
2005 JUN 20 ... with Schering AG, continue to seek approval of and successfully commercialize Plenaxis in the European Union and Schering AG's other licensed territories. The ...
Subject: Business Update
Price: $3.00
*
Pharma company reports improved financial results
2005 JUN 6 ... compared to approximately $461,000 for the corresponding period in 2004. Sales of Plenaxis in the first quarter of 2005 were approximately $804,000, compared to fourth quarter ...
Subject: Finance
Price: $3.00
*
Pharma company offers status of marketing authorization application for Plenaxis
2005 APR 25 ... provided an update on the status of its marketing authorization application (MAA) for Plenaxis in Germany. As previously disclosed, the company's MAA for...
Subject: Alzheimer Disease
Price: $3.00
*
U.S. CMS issues coverage determination for Abarelix
2005 APR 11 ... Medicaid Services (CMS) has issued a national coverage determination (NCD) for Abarelix (Plenaxis). PRAECIS filed a formal request with CMS for a NCD in order to ensure ...
Subject: Prostate Cancer
Price: $3.00
*

Results 1 - 9

-----------------------
Home | Free Newsletters | Products | Article Library | About Us | Contact | Privacy Policy | Search | Visit VerticalNews.com
Copyright © 2009 NewsRx		 PR Login